Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03093220|
Recruitment Status : Unknown
Verified March 2017 by Peking University People's Hospital.
Recruitment status was: Recruiting
First Posted : March 28, 2017
Last Update Posted : March 28, 2017
Community-acquired pneumonia (CAP) is a heterogeneous disease causing great morbidity, mortality and health care burden globally. Typing methods for discriminating different clinical conditions of the same disease are essential to a better management of CAP. Traditional typing systems based separately on clinical manifestations (such as PSI and CURB-65), pathogens(bacterial types, virulence, drug resistance, etc) or host immune state (immunocompetent, immunocompromised or immunodeficiency). Thus, they are barely able to represent the real disease status nor to precisely predict the mortality.
As the development of multi-omic technologies, the relatedness of different phenotypes at a molecular level have revolutionized our ability to differentiate among patients. Our study is aimed at establishing a novel molecular typing method of CAP. Multi-omic (including genomics, transcriptomes, and metabolisms) data obtained from enrolled CAP patients and isolated pathogens would be integrated analyzed and interpreted. Tthe investigators believe that an appropriate molecular typing method would lead to revolutionary changes in current arrangements of CAP.
|Condition or disease|
|Respiratory Infections Genetic Disorder Community-Acquired Infections Host-Pathogen Interactions|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Molecular Typing of Adult Community-acquired Pneumonia in China|
|Estimated Study Start Date :||March 2017|
|Estimated Primary Completion Date :||March 31, 2018|
|Estimated Study Completion Date :||December 2018|
all adult patients (aged > 16 years) admit to the 4 hospitals between March 2017 and March 2018 with CAP will be enrolled
- 30 day mortality [ Time Frame: 30 days after the onset of CAP ]all-cause death in 30 days after the onset of CAP
- complications [ Time Frame: 30 days after the onset of CAP ]nonfatal complications including critical organic or systematic dysfunction
Biospecimen Retention: Samples With DNA
- Lower respiratory tract specimens including sputum, endotracheal aspiration and bronchoalveolar lavage fluid.
- Peripheral whole blood samples
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03093220
|Contact: Yali Zheng, Dr||15011451515 ext email@example.com|
|Peking University People's Hospital||Recruiting|
|Beijing, Beijing, China, 100044|
|Contact: Yali Zheng, Dr 15011451515 ext 86 firstname.lastname@example.org|
|Study Chair:||Zhancheng Gao, Professor||Department of Respiratory Critical Care Medicine|